Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00344513|
Recruitment Status : Completed
First Posted : June 26, 2006
Last Update Posted : November 24, 2020
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure, Congestive||Drug: Beta-blockers including Carvedilol Drug: ACE inhibitors||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||50000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients|
|Actual Study Start Date :||December 16, 2002|
|Actual Study Completion Date :||June 30, 2005|
- Drug: Beta-blockers including Carvedilol
- Drug: ACE inhibitors
Other Name: Beta-blockers including Carvedilol
- Evaluate the number and percentage of eligible patients who are discharged on optimal therapy. Evaluate all HF indicators recommended by JCAHO and CMS.
- Mortality Recurrent hospitalization Number of patients receiving beta-blockers therapy within 60 to 90 days of initiation and mean beta-blocker dose 60-90 days following discharge.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00344513
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|